Jefferies Maintains a 'Buy' on Biogen (BIIB) on Strong Q2; Adjusting Numbers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA
6. AVGO
7. SPCX
8. DE
9. OSIS
10. REAX

July 25, 2012 10:05 AM EDT
Get Alerts BIIB Hot Sheet
Price: $216.78 +1.13%

Rating Summary:
    28 Buy, 15 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Biogen (NASDAQ: BIIB) price target of $164.00 (from $154.00).

Analyst, Thomas Wei, said, "Strong 2Q12 results were driven by a surprise in Avonex upside. Tysabri sales were impacted by factors which we see as non-material to underlying growth, and we remain encouraged by strong positive Tysabri trends in new patient adds (+2,400 vs +1,900 in 1Q) with modest discontinuations and continued growth in TOUCH forms."

FY12 lowered from $6.16 to $5.68 and FY13 from $6.99 to $6.52.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $139.48 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co